Allogene Therapeutics Inc
ALLO
Get informed when a big investor buys or sells
+ FollowMarket Cap$614.38M
Close$
$-0.14
108.3% downside
Current Fair Value
108.3% downsideOvervalued by 108.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $614.38 Million |
|---|---|
| Enterprise Value | $646.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.87 |
| Beta | 0.48 |
| Outstanding Shares | 328,930,269 |
Return
| Return on Equity | -37.94% |
|---|---|
| Return on Assets | -30.08% |
| Return on Invested Capital | -36.91% |
Valuation & Multiples
| P/E Ratio | -2.66 |
|---|---|
| PEG | 16.37 |
| Price to Sales | - |
| Price to Book Ratio | 1.72 |
| Enterprise Value to Revenue | 139.25 |
| Enterprise Value to EBIT | -3.38 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$2,500
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$2,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5608▲ 11.70% |
|---|---|
| Total Calls | 295,100▲ 5.54% |
| Total Puts | 165,500▲ 33.36% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 95.75%▲ 19.09% |
|---|---|
| Total Invested | $656.73M▲ 47.67% |
| Investors Holding | 216▲ 2.00% |
ESG Score
No data